Clinical Trials in Boston

Showing 6921-6940 of 17,836 trials

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

NCT02004028

This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery) study in subjects with malignant pleural mesothelioma who are eligible for surgery. Subjects will receive VS-6063 (defactinib) 400 mg twice daily for 12, 21, or 35 days or 100 mg formulation twice daily for 21 days. Pre- and post-treatment biopsies and blood samples will be collected. The purpose of this study is to assess biomarker responses from tumor tissue. The safety, pharmacokinetics, and tumor response rate to VS-6063 (defactinib) will be also be assessed.

Malignant Pleural Mesothelioma

Verastem, Inc.35 participantsStarted Dec 2013

Boston, Massachusetts, United States

COMPLETED< 1 mile

Pediatric KIDney Stone (PKIDS) Care Improvement Network

NCT04285658

The goals of this study are to improve the ability of pediatric patients and their caregivers to select surgical treatment options for kidney stones and to enable urologists to use techniques that result in the best outcomes for these surgeries.

Kidney StoneNephrolithiasis

Children's Hospital of Philadelphia1,290 participantsStarted Apr 2020

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +28 more locations

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Pediatric KIDney Stone (PKIDS) Care Improvement Network

Find Trials by Condition in Boston

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

The Feasibility of VR for OUD

Practice of Acceptance, Awareness, and Compassion in Caregiving (PAACC)

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Lung EpiCheck Biomarkers Development Study

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis